Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Sintilimab in HCC with Microvascular Invasion
NCT06089369Phase 3Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06089369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06089369.